Synthesis of HIV Protease Inhibitor ABT-378 (Lopinavir)

A large scale process for the synthesis of HIV protease inhibitor candidate ABT-378 has been developed which utilizes an intermediate common to the synthesis of ritonavir, Abbott's first generation compound. The synthesis relies on the sequential acylation of this intermediate which is carried...

Full description

Saved in:
Bibliographic Details
Published in:Organic process research & development Vol. 4; no. 4; pp. 264 - 269
Main Authors: Stoner, Eric J, Cooper, Arthur J, Dickman, Daniel A, Kolaczkowski, Lawrence, Lallaman, John E, Liu, Jih-Hua, Oliver-Shaffer, Patricia A, Patel, Ketan M, Paterson, Joseph B, Plata, Daniel J, Riley, David A, Sham, Hing. L, Stengel, Peter J, Tien, Jien-Heh J
Format: Journal Article
Language:English
Published: American Chemical Society 01-07-2000
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A large scale process for the synthesis of HIV protease inhibitor candidate ABT-378 has been developed which utilizes an intermediate common to the synthesis of ritonavir, Abbott's first generation compound. The synthesis relies on the sequential acylation of this intermediate which is carried through as a mixture of diastereomers until the penultimate step. A synthesis of acid 5, derived from l-valine, is also reported.
ISSN:1083-6160
1520-586X
DOI:10.1021/op990202j